KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Free Cash Flow (2018 - 2025)

Historic Free Cash Flow for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to -$7.5 million.

  • Adaptive Biotechnologies' Free Cash Flow rose 7250.54% to -$7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$62.9 million, marking a year-over-year increase of 4505.17%. This contributed to the annual value of -$98.9 million for FY2024, which is 4080.03% up from last year.
  • Adaptive Biotechnologies' Free Cash Flow amounted to -$7.5 million in Q3 2025, which was up 7250.54% from -$13.1 million recorded in Q2 2025.
  • In the past 5 years, Adaptive Biotechnologies' Free Cash Flow ranged from a high of -$7.5 million in Q3 2025 and a low of -$74.1 million during Q1 2021
  • Over the past 5 years, Adaptive Biotechnologies' median Free Cash Flow value was -$39.9 million (recorded in 2024), while the average stood at -$40.6 million.
  • In the last 5 years, Adaptive Biotechnologies' Free Cash Flow plummeted by 11431.34% in 2021 and then skyrocketed by 7250.54% in 2025.
  • Adaptive Biotechnologies' Free Cash Flow (Quarter) stood at -$63.1 million in 2021, then soared by 48.37% to -$32.6 million in 2022, then grew by 13.3% to -$28.2 million in 2023, then soared by 55.47% to -$12.6 million in 2024, then soared by 40.05% to -$7.5 million in 2025.
  • Its Free Cash Flow stands at -$7.5 million for Q3 2025, versus -$13.1 million for Q2 2025 and -$29.7 million for Q1 2025.